LEI:
549300Q7EXQQH6KF7Z84
01 November
2024
RTW Biotech Opportunities
Ltd
New Investment in Series C Round of
Evommune, Inc.
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to note a new
portfolio company investment in Evommune, Inc.
("Evommune"). The Company received a legacy
position in Evommune earlier this year when it acquired the assets
of Arix Bioscience. This Series C investment signifies the
Company's long-term commitment to Evommune's future
success.
The Company, alongside other
investment vehicles managed by RTW Investments, LP (the
"Investment Manager"),
participated in Evommune's Series C round, raising $115 million to
advance a pipeline of assets targeting chronic inflammatory
diseases. Proceeds will be used to support advancement of lead
clinical programs in chronic urticaria and atopic dermatitis,
including multiple Phase 2 studies of EVO756, which plays a pivotal
role in mast cell activation and neuroinflammation and has the
potential to be a very targeted, safe and effective oral
therapeutic option for multiple mast cell-mediated
diseases.
Evommune is a clinical-stage
biotechnology company discovering and developing new ways to treat
immune-mediated inflammatory diseases.
Roderick Wong,
Managing Partner and CIO at
the Investment Manager said, "We are thrilled to
continue our support for Evommune. We believe in Evommune's vision
and their potential to make a significant impact in the lives of
patients. Our ongoing investment after acquiring the position in
our merger with Arix underscores the value of that transaction and
our confidence in their promising pipeline of
therapies."
The full text of the announcement can be
accessed at:
https://evommune.com/.
For
Further Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Cadarn Capital (PR & Communications/Distribution & IR
Partner)
|
+44
79 8418 4461
|
|
Lucy Clark (PR)
|
Lucy@cadarncapital.com
|
|
David Harris
(Distribution)
|
+44
73 6888 3211
david@cadarncapital.com
|
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield
|
+44
20 7260 1000
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44 14 8170 3100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW) is an investment fund focused on identifying transformative
assets with high growth potential across the biopharmaceutical and
medical technology sectors. Driven by a long-term approach to
support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and
technologies that can significantly improve patients' lives. RTW
Biotech Opportunities Ltd is managed by RTW Investments, LP, a
leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********